AATec Medical Secures EUR 4 Million for Respiratory Drug Development

AATec Medical GmbH has secured EUR 4 million in pre-series A funding to advance its lead drug candidate, ATL-105, for clinical development targeting non-cystic fibrosis bronchiectasis (NCFB). The financing is supported by Germany’s Federal Agency for Disruptive Innovation (SPRIND) and various investors. ATL-105 is based on recombinant alpha-1 antitrypsin, targeting chronic respiratory inflammation.

This funding will support ATL-105's entry into clinical trials by 2026, addressing a need for effective NCFB treatments. Current options, which include antibiotics and physical therapy, only offer symptomatic relief.

Dr. Rüdiger Jankowsky, CEO of AATec, states that this drug delivery approach maximizes therapeutic effectiveness while minimizing systemic side effects. SPRIND's backing underscores the drug’s innovative potential in treating inflammatory lung diseases.